Hepatitis C virus and depression in drug users

American Journal of Gastroenterology

Volumn 93, Issue 5, 1998, Pages 785-789

  Johnson, Mark E ^a   Fisher, Dennis G ^a   Fenaughty, Andrea ^a   Theno, Shelley A ^a  

^a UNIVERSITY OF ALASKA ANCHORAGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY; INTERFERON;

ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM;

ADOLESCENT; ADULT; DEPRESSION; FEMALE; HEPATITIS C; HUMANS; INTERFERONS; MALE; MIDDLE AGED; SUBSTANCE-RELATED DISORDERS;

EID: 0032081117     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1998.225_a.x     Document Type: Article

References (31)

1. 1. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Eng J Med. 1994;330:751-6.
2. 2. Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med. 1987;147:1577-80.
3. 3. Schnittman SM, Vogel S, Baseler M, et al. A phase I study of interferon-2b in combination with interleukin-2 in patients with human immunodeficiency virus infection. J Infect Dis 1994;169:981-9.
4. 4. Smedley H, Katrak M, Sikora K, et al. Neurological effects of recombinant human interferon. Br Med J 1983;286:262-4.
5. 5. Rohatiner AZS, Prior PF, Burton AC, et al. Central nervous system toxicity of interferon. Br J Cancer 1983;47:419-22.
6. 6. Johnson DH, Hande KR, Hainsworth JD, et al. Neurotoxicity of interferon. Cancer Treatment Reports 1983;67:958-91.
7. 7. Adams F, Quesada JR, Gutterman JU. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 1984;252:938-41.
8. 8. Hakozaki Y, Shirahama T, Katou M, et al. A controlled study to determine the optimal dose regime of interferon-2b in chronic hepatitis C. Am J Gastroenterol 1995;90:1246-9.
9. 9. McDonald EM, Mann AH, Thomas HC. Interferon as mediators of psychiatric morbidity. Lancet 1987;2:1175-7.
10. 10. Fisher DG, Fenaughty AM, Paschane AA, et al. Hepatitis C virus infection among Alaskan drug users. Am J Public Health 1997;87: 1722-4.
11. 11. Fisher DG, Kuhrt-Hunstiger TI. Prevalence and risk factors for hepatitis B in IVDUs. In: Abstracts of the 121st Annual American Public Health Association Meeting and Exhibition. 1993, 2072, p. 143.
12. 12. Kuhrt-Hunstiger TI, Fisher DG. Prevalence and associated risk factors for hepatitis B virus in intravenous drug users not in treatment in Anchorage, Alaska. Arctic Med Res 1993;53:625-7.
13. 13. Kuhrt-Hunstiger TI, Fisher DG. Hepatitis B: How unique is Alaska? In: Abstracts of the 122nd Annual Meeting and Exhibition of the American Public Health Association, Washington, DC (3106-310), 1994.
14. 14. Bell J, Batey RG, Farell GC, et al. Hepatitis C virus in intravenous drug users. Med J Aust 1990;153:274-6.
15. 15. Crofts N, Hopper JL, Bowden DS, et al. Hepatitis C virus infection among a cohort of Victorian injecting drug users. Med J Aust 1993; 159:237-41.
16. 16. Fisher DG, Kuhrt-Hunstiger TI, Orr S, et al. Hepatitis B: Validity of drug users' self report. Psych of Addictive Behaviors (in press).
17. 17. Woodfield DG, Harness M, Rix-Trott K, et al. Identification and genotyping of hepatitis C virus in injectable and oral drug users in New Zealand. Aust N Z J Med 1994;24:47-50.
18. 18. Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990;264:2231-5.
19. 19. Hesselbrock MN, Meyer RE, Keener JJ. Psychopathology in hospitalized alcoholics. Arch Gen Psychiatry 1985;42:1050-5.
20. 20. Khantizian EJ, Treece C. DSM-III psychiatric diagnoses of narcotic addicts. Arch Gen Psychiatry 1985;42:1067-71.
21. 21. Ross HE, Glaser FB, Germanson F. The prevalence of psychiatric disorders in patients with alcohol and other drug problems. Arch Gen Psychiatry 1988;45:1023-31.
22. 22. Rounsaville BJ, Weissman MM, Kleber HD, et al. Heterogeneity of psychiatric diagnosis in treated opiate addicts. Arch Gen Psychiatry 1982;39:161-6.
23. 23. Johnson ME, Fisher DG, Estrada AL, et al. Use of the Center for Epidemiological Studies-Depression Scale with drug abusers not currently in treatment. Paper presented at the Annual Conference on Psychopathology, Psychopharmacology, Substance Abuse, and Culture, Los Angeles. 1995, October.
24. 24. Singh N, Gayowski T, Wagener MM, et al. Psychologic stress, depression and quality of life in patients with liver disease due to hepatitis C virus. AASLD Abstracts: Hepatology 1996;24:295A (abstract).
25. 25. National Institute on Drug Abuse. Risk behavior assessment. Rockville, MD: National Institute on Drug Abuse (Community Research Branch), 1991.
26. 26. Dowling-Guyer S, Johnson ME, Fisher DG, et al. Reliability of drug users' self-reported HIV risk behaviors and validity of self-reported recent drug use. Assessment 1994;1:383-92.
27. 27. Fisher DG, Needle R, Weatherby N, et al. Reliability of drug user self-report. IXth International Conference on AIDS, Berlin, Germany (PO - C35-3355), 1993 (abstract).
28. 28. Needle R, Fisher DG, Weatherby N, et al. The reliability of self-reported HIV risk behaviors of drug users. Psych Addictive Behaviors 1995;9:242-50.
29. 29. Weatherby NL, Needle R, Cesari H, et al. Validity of self-reported drug use among injection drug users and crack cocaine users recruited through street outreach. Evaluation and Program Planning 1994;17: 347-55.
30. 30. Radloff L. The CES-D Scale: A self-report scale for research in the general population. Applied Psychological Measurement 1977;1:385-401.
31. 31. Ensel W. Measuring depression: the CES-D Scale. In: Lin N, Dean A, Ensel W, eds. Social support, life events and depression. Orlando: Academic Press, 1986:51-70.